Clinical Trials Directory

Trials / Completed

CompletedNCT02017990

Plasma Marine n-3 Polyunsaturated Fatty Acids and Patient and Graft Survival

The Levels of Marine n-3 Polyunsaturated Fatty Acids in Plasma Phospholipids as a Prognostic Marker of Mortality and Graft Loss Endpoints in Renal Transplant Recipients.

Status
Completed
Phase
Study type
Observational
Enrollment
2,002 (actual)
Sponsor
Oslo University Hospital · Academic / Other
Sex
All
Age
16 Years
Healthy volunteers
Not accepted

Summary

This study will evaluate the association between n-3 polyunsaturated fatty acids and patient and graft survival. The association between other fatty acids and mortality and graft loss endpoints will also be evaluated.

Detailed description

This observational study focuses on the effects of marine n-3 polyunsaturated fatty acids (PUFAs) intake, measured as fatty acid levels in plasma phospholipids, and mortality and graft loss endpoints in renal transplant recipients. Data on morbidity, mortality and graft loss in The Norwegian Renal Registry is matched against data on fatty acid composition in a large renal transplantation cohort of approximately 2000 patients with a median follow up time of about 5 years. It is a follow up study, although retrospectively evaluated. It will evaluate the role of marine n-3 PUFAs as a prognostic marker in renal transplantation by investigating the association between the levels (weight percentage of total fatty acids) of marine n-3 PUFAs in plasma phospholipids and events, including mortality and graft loss.

Conditions

Timeline

Start date
1999-10-01
Primary completion
2012-08-01
Completion
2013-06-01
First posted
2013-12-23
Last updated
2014-03-03

Locations

1 site across 1 country: Norway

Source: ClinicalTrials.gov record NCT02017990. Inclusion in this directory is not an endorsement.